scispace - formally typeset
V

Vojo Deretic

Researcher at University of New Mexico

Publications -  278
Citations -  51981

Vojo Deretic is an academic researcher from University of New Mexico. The author has contributed to research in topics: Autophagy & Phagosome. The author has an hindex of 101, co-authored 269 publications receiving 45639 citations. Previous affiliations of Vojo Deretic include University of Texas at Austin & University of Michigan.

Papers
More filters
Book ChapterDOI

Autophagic proteolysis of long-lived proteins in nonliver cells.

TL;DR: A protocol to quantify autophagic degradation of longlived proteins in macrophages is described, based on a pulse-chase approach, whereby cellular proteins are radiolabeled by an isotopically marked amino acid, the short-lived, rapidly turned over, proteins are allowed to be degraded during a long chase period, and then the remaining, stable radolabeled proteins are subjected to autophotic degradation.
Journal ArticleDOI

Endosomal hyperacidification in cystic fibrosis is due to defective nitric oxide–cylic GMP signalling cascade

TL;DR: The endosomal hyperacidification and excessive proinflammatory response in CF are in part due to deficiencies in NO‐ and cGMP‐regulated processes and can be pharmacologically reversed using PDE5 inhibitors.
Journal ArticleDOI

Sustained activation of autophagy suppresses adipocyte maturation via a lipolysis-dependent mechanism

TL;DR: It is shown that inhibiting MTORC1 by RPTOR deficiency led to autophagic sequestration of lipid droplets, formation of LD-containing lysosomes, and elevation of basal and isoproterenol-induced lipolysis in vivo and in primary adipocytes.
Journal ArticleDOI

Targeted pulmonary delivery of inducers of host macrophage autophagy as a potential host-directed chemotherapy of tuberculosis.

TL;DR: This review addresses the advantages and disadvantages of delivering drugs to induce autophagy in M. tuberculosis-infected macrophages and term here this (still experimental) approach, of compartment-targeting, autophagic-based, host-directed therapy as "Track-II antituberculosis chemotherapy."